Panobinostat Potentiates Temozolomide Effects and Reverses Epithelial–Mesenchymal Transition in Glioblastoma Cells
Glioblastoma is the most common form of glioma, as well as the most aggressive. Patients suffering from this disease have a very poor prognosis. Surgery, radiotherapy, and temozolomide are the only approved treatments nowadays. Panobinostat is a pan-inhibitor of histone deacetylases (HDACs) that has...
Main Authors: | Alejandro Urdiciain, Bárbara Meléndez, Juan A. Rey, Miguel A. Idoate, Javier S. Castresana |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-02-01
|
Series: | Epigenomes |
Subjects: | |
Online Access: | http://www.mdpi.com/2075-4655/2/1/5 |
Similar Items
-
Panobinostat and its combination with 3-deazaneplanocin-A induce apoptosis and inhibit In vitro tumorigenesis and metastasis in GOS-3 glioblastoma cell lines
by: Javier de la Rosa, et al.
Published: (2018-01-01) -
Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines
by: Alejandro Urdiciain, et al.
Published: (2021-05-01) -
In vitro therapy against glioblastoma cells by 3-Dezaneplanocin-A, panobinostat, and temozolomide
by: Javier de la Rosa, et al.
Published: (2018-01-01) -
Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
by: Pingde Zhang, et al.
Published: (2018-01-01) -
Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
by: Yu-Ling Tsai, et al.
Published: (2020-09-01)